

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-032024-000728

Date: 01/11/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

I am researching the incidence and treatment of Urothelial and Endometrial Cancer. I would greatly appreciate if you could answer the following questions.

Q1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Carboplatin single agent or in any other combination
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Cisplatin single agent or in any other combination
- Cisplatin with Gemcitabine
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Other active systemic anti-cancer therapy
- Palliative care only

Q2. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Q3. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Pembrolizumab + Lenvatinib (Keytruda + Lenvima)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT

Q4. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Response

| Questions | Responses |
|---|--|
| <p>Q1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:</p> <ul style="list-style-type: none"> • Atezolizumab (Tecentriq) • Avelumab (Bavencio) • Carboplatin single agent or in any other combination • Carboplatin with Gemcitabine • Carboplatin with Paclitaxel • Cisplatin single agent or in any other combination • Cisplatin with Gemcitabine • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Other active systemic anti-cancer therapy • Palliative care only | <p>The Trust does not hold this information in a reportable format. In order to provide this, it would require a manual trawl of patient’s records, which is exempt under Section 40 (Personal Information) of the Freedom of Information Act.</p> |
| <p>Q2. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?</p> | <p>Yes</p> |
| <p>Q3. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:</p> <ul style="list-style-type: none"> • Dostarlimab (Jemperli) • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Pembrolizumab + Lenvatinib (Keytruda + Lenvima) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT | <ul style="list-style-type: none"> • Dostarlimab (Jemperli) – < 5 • Hormone therapy (Progesterone or Letrozole) - Not recorded in ChemoCare • Pembrolizumab (Keytruda) monotherapy – 0 • Pembrolizumab + Lenvatinib (Keytruda + Lenvima) – 6 • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 70 • Any other SACT – 17 <p>Please note as per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the persons involved and cause distress to Families or Friends. The number of patients treated for endometrial cancer in the past 3 months is less than 5, so Exemption Section 40(2) of the Freedom of Information Act is applied.</p> |
| <p>Q4. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?</p> | <p>The Trust does not hold this information in a reportable format. In order to provide this, it would require a manual trawl of patient’s records, which is exempt under Section 40 (Personal Information) of the Freedom of Information Act.</p> |

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust